IPO Year: 2025
Exchange: NASDAQ
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present a company overview at the Jefferies 2025 Global Healthcare Conference on Thursday, June 5, 2025 at 2 p.m. ET. A live webcast will be available in the Investors section of the company's website at www.MazeTx.com and archived for 60 days following the presentation. About Maze TherapeuticsMaze Therapeutics is a clinical-stage biopharmaceutica
MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease; Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in Q3 2025 Strong Balance Sheet with $294.4 Million in Cash and Cash Equivalents, Expected to Provide Cash Runway into H2 2027 SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today reported financial results for the first quarter ended March 31, 2025, and reiterated upcoming milestones. "With two clinical pro
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present a company overview and participate in one-on-one meetings at the 3rd Annual H.C. Wainwright BioConnect Investor Conference on Tuesday, May 20, 2025. The presentation will be held at 11 a.m. ET and will be available in the Investors section of the company's website at mazetx.com. A replay of the presentation will be archived for 60 days. I
MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in H2 2025 Raised $140 Million in Gross Proceeds in Upsized IPO in February 2025, Providing Expected Cash Runway into H2 2027 SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, cardiovascular and metabolic diseases, today reported financial results for the fourth quarter and year ended December 31, 2024, highlighted recent progress and reitera
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases, today announced the first patient has been dosed in the company's Phase 2 clinical trial, the HORIZON Study, of MZE829 in patients with APOL1 kidney disease (AKD). MZE829 is an oral, small molecule APOL1 inhibitor that Maze is advancing as a potential treatment for people living with AKD, a subset of chronic kidney disease estimated to affect over one million patients in the United Stat
4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
SCHEDULE 13G - Maze Therapeutics, Inc. (0001842295) (Subject)
SCHEDULE 13G - Maze Therapeutics, Inc. (0001842295) (Subject)
10-Q - Maze Therapeutics, Inc. (0001842295) (Filer)
8-K - Maze Therapeutics, Inc. (0001842295) (Filer)
SCHEDULE 13G - Maze Therapeutics, Inc. (0001842295) (Subject)
SCHEDULE 13G - Maze Therapeutics, Inc. (0001842295) (Subject)
10-K - Maze Therapeutics, Inc. (0001842295) (Filer)
8-K - Maze Therapeutics, Inc. (0001842295) (Filer)
SCHEDULE 13G - Maze Therapeutics, Inc. (0001842295) (Subject)
SCHEDULE 13G - Maze Therapeutics, Inc. (0001842295) (Subject)